Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL. Martin P, Bartlett NL, Chavez JC, Reagan JL, et al. Blood 2022;139:1147-1159.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Martin P, Bartlett NL, Chavez JC, Reagan JL, et al. Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL. Blood 2022;139:1147-1159.
PMID: 34428285